Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Insider Beth Hecht Sells 40,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 40,000 shares of the company’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the sale, the insider now owns 1,353,510 shares of the company’s stock, valued at $7,349,559.30. This represents a 2.87 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Xeris Biopharma Stock Performance

NASDAQ:XERS traded up $0.38 during mid-day trading on Friday, hitting $5.81. 6,249,809 shares of the company’s stock traded hands, compared to its average volume of 1,660,213. The company has a fifty day moving average of $3.83 and a 200 day moving average of $3.38. Xeris Biopharma Holdings, Inc. has a twelve month low of $1.69 and a twelve month high of $5.91. The company has a market capitalization of $894.39 million, a P/E ratio of -12.91 and a beta of 2.32.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Craig Hallum upped their target price on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a report on Friday, March 7th. Piper Sandler reissued a “neutral” rating and issued a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners boosted their price target on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, March 7th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $5.92.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. increased its position in Xeris Biopharma by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after buying an additional 2,954 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Xeris Biopharma by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock valued at $273,000 after buying an additional 3,447 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in Xeris Biopharma by 31.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company’s stock valued at $55,000 after buying an additional 3,847 shares in the last quarter. GPS Wealth Strategies Group LLC increased its holdings in shares of Xeris Biopharma by 6.2% in the fourth quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock valued at $227,000 after purchasing an additional 3,900 shares during the period. Finally, Janney Montgomery Scott LLC increased its holdings in shares of Xeris Biopharma by 31.4% in the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock valued at $78,000 after purchasing an additional 5,500 shares during the period. 42.75% of the stock is owned by institutional investors and hedge funds.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.